Ferring, Aventis To Pay $4.8M To End Drug Antitrust Suit
Ferring BV and Aventis Pharmaceuticals Inc. have settled for $4.75 million a proposed class' allegations that the companies thwarted generic competition for anti-diuretic drug DDAVP by fraudulently obtaining a patent on...To view the full article, register now.
Already a subscriber? Click here to view full article